Group B Streptococcus (GBS) Epidemiology

Key Highlights

• Group B Streptococcus (GBS) colonization can be symptomatic (leading to infections) or asymptomatic (no symptoms). Most GBS-colonized individuals remain asymptomatic carriers.
• Type-specific incident cases of GBS were categorized into invasive GBS infections and noninvasive GBS infections. Invasive GBS infections penetrate sterile sites (bloodstream, meninges), causing severe systemic illness, while noninvasive infections remain localized (urinary tract, skin) with milder symptoms. As per our estimates, incident cases of noninvasive infections were higher in the 7MM.
• GBS colonization during pregnancy is rare but can lead to neonatal infections, including sepsis, pneumonia, and meningitis. Early-onset GBS disease occurs within the first week of life, while late-onset disease occurs from the first week to several months after birth.

DelveInsight’s “Group B Streptococcus (GBS) – Epidemiology – 2034” report delivers an in-depth understanding of Group B Streptococcus (GBS), historical and forecasted epidemiology of Group B Streptococcus (GBS) in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2021-2034

Group B Streptococcus (GBS) Disease Understanding

Group B Streptococcus (GBS) Overview

Group B Streptococcus (GBS), or Streptococcus agalactiae, is a bacteria commonly found in the gastrointestinal and genital tracts of adults, with around 10–30% of pregnant women carrying it. GBS can lead to invasive infections like sepsis, meningitis, and pneumonia, particularly in newborns and elderly adults. It can also cause less severe noninvasive infections such as urinary tract infections and skin infections. GBS colonization in pregnant women poses a risk of transmission to newborns during childbirth, potentially resulting in serious early-onset GBS disease. Preventive measures include maternal screening, antibiotics during labor, and ongoing research for vaccines to mitigate the impact of GBS-related infections.

Group B Streptococcus (GBS) Diagnosis

Diagnosing Group B Streptococcus (GBS) infection involves clinical evaluation, laboratory testing, and risk assessment. In pregnant women, GBS screening is conducted during late pregnancy to identify carriers and administer appropriate intrapartum antibiotics to prevent transmission to newborns; for suspected GBS infections in other individuals, cultures of blood, cerebrospinal fluid, or other body fluids are examined to isolate and identify the bacteria. Prompt diagnosis relies on clinical suspicion, accurate testing, and adherence to established guidelines to ensure timely treatment and prevent potential complications.

Further details related to diagnosis are provided in the report…

Group B Streptococcus (GBS) Epidemiology

As the market is derived using a patient-based model, the Group B Streptococcus (GBS) epidemiology chapter in the report provides historical as well as forecasted total incident cases of Group B Streptococcus (GBS) segmented by type-specific incident cases of Group B Streptococcus (GBS) and age-specific incident cases of Group B Streptococcus (GBS), in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2021 to 2034. The total incident cases in the 7MM comprised approximately 230,000 cases in 2022 and are projected to increase during the forecast period.

• The total number of incident cases of Group B Streptococcus (GBS) infection in 2022 across the seven major markets (7MM) was approximately 230,000.
• In 2022, the US accounted for the maximum patient share in the 7MM, i.e., 66% of the total incident cases in the 7MM.
• In the age-specific distribution of invasive Group B Streptococcus (GBS) cases in 2022, the maximum number of cases were observed in the age group >18 years, including (non-pregnant adults and pregnant women). Age-group 0–17 years were categorized into early-onset GBS, late-onset GBS, 3 months-17 year age groups.
• Among EU4, Germany accounted for the highest number of Group B Streptococcus (GBS) cases, followed by the UK, whereas Spain accounted for the lowest number of cases in 2022.
• Type-specific Incident Cases of GBS Infection were categorized into Invasive GBS infection and Noninvasive GBS infection, with 34,000 and 118,000 cases, respectively, in 2022.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Group B Streptococcus (GBS) evolving treatment landscape, patient reliance on conventional therapies, patient therapy switching acceptability, drug uptake, along with challenges related to accessibility, including Pulmonologists, HCPs, Physicians, and others.

DelveInsight’s analysts connected with 10+ KOLs to gather insights; however, interviews were conducted with 5+ KOLs in the 7MM. Centers like Louisiana State University and LSU Health Sciences Center were contacted. Their opinion helps understand and validate current and emerging therapy treatment patterns or Group B Streptococcus (GBS) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Scope of the Report

• The report covers a segment of key events, an executive summary, descriptive overview of Group B Streptococcus (GBS), explaining its causes, signs and symptoms, pathogenesis, and currently available therapies.
• Comprehensive insight into the epidemiology segments and forecasts, disease progression, and treatment guidelines has been provided.
• The report provides an edge while developing business strategies, understanding trends, expert insights/KOL views, and patient journey in the 7MM.
• A detailed review of current challenges in establishing the diagnosis.

Group B Streptococcus (GBS) Report Insights

• Patient Population
• Country-wise Epidemiology Distribution
• Age-wise cases of Group B Streptococcus (GBS)

Group B Streptococcus (GBS) Report Key Strengths

• Ten Years Forecast
• The 7MM Coverage
• Group B Streptococcus (GBS) Epidemiology Segmentation

Group B Streptococcus (GBS) Report Assessment

• Current Diagnostic Practices

Epidemiology Insights

• What are the disease risk, burdens, and unmet needs of Group B Streptococcus (GBS)? What will be the growth opportunities across the 7MM concerning the patient population with Group B Streptococcus (GBS)?
• What is the historical and forecasted Group B Streptococcus (GBS) patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Why are the diagnosed prevalence rates in European countries lower than in Japan? Why are Group B Streptococcus (GBS) patients not diagnosed as efficiently as in Japan?
• Which Type has a higher prevalence of Group B Streptococcus (GBS)?
• Which age group of Group B Streptococcus (GBS) has a high patient share?

Reasons to Buy

• Insights on patient burden/disease, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the age-specific Group B Streptococcus (GBS) prevalence cases in varying geographies over the coming years.
• A detailed overview of age-specific and type-specific incident cases of Group B Streptococcus (GBS) is an inclusion.
• To understand the perspective of key opinion leaders around the current challenges with establishing the diagnosis and insights on the recurrent and treatment-eligible patient pool.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.

Frequently Asked Questions (FAQs)

How common is GBS colonization in pregnant women?

GBS colonization occurs in approximately 10–30% of pregnant women, varying by population and region.

What are the risks of GBS colonization during pregnancy?

GBS colonization increases the risk of transmission to newborns during childbirth, potentially causing early-onset GBS disease, which can be severe.

What are the symptoms of GBS infection in newborns?

Symptoms include fever, difficulty breathing, lethargy, poor feeding, and irritability. Serious cases can lead to sepsis, pneumonia, and meningitis.

How is GBS infection prevented in newborns?

Prevention strategies include maternal screening late in pregnancy, administering antibiotics during labor if GBS-positive, and ongoing research into GBS vaccines.

Can GBS infections affect adults as well?

Yes, GBS infections can affect adults, particularly the elderly or those with underlying health conditions, causing conditions like sepsis, pneumonia, and urinary tract infections."